Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors

LESSONS LEARNED. Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study. Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected. No efficacy conclusion c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Cao, Junning, Ji, Dongmei, Chen, Zhiyu, Shen, Weina, Wang, Jin, Li, Baoyue, Chi, Haidong, Long, Amanda, Gao, Ling, Li, Jin
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469595/
https://ncbi.nlm.nih.gov/pubmed/28465370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0137
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares